-
Vembrolizumab: A 'first in class' ADC to challenge first-line lymphoma treatment
Time of Update: 2022-05-02
At the 2021 American Society of Hematology (ASH) annual meeting, vebotuzumab combined with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) versus R-CHOP (rituximab) The phase III POLARIX study of monoclonal antibody, cyclophosphamide, doxorubicin, vincristine, prednisone) in the first-line treatment of DLBCL has released detailed data and published it simultaneously in the New England Journal of Medicine .
-
The Yangtze River Delta (Shanghai, Zhejiang and Anhui) Alliance will open bids on February 25
Time of Update: 2022-05-02
On February 23, 2022, the Shanghai Pharmaceutical Centralized Bidding and Purchasing Administration issued the precautions for submitting application materials for centralized drug procurement in the Yangtze River Delta (Shanghai, Zhejiang and Anhui) Alliance .
-
A group of pharmaceutical companies announced the completion of financing, which will be used to speed up the research and development of new products
Time of Update: 2022-05-02
(hereinafter referred to as "Qinhao Pharmaceutical") also announced that the company has completed a series B financing of several hundred million yuan .
(“Tianrui Diagnosis”), a provider of medical diagnostic service solutions, also announced the completion of the B+ round of financing of 100 million yuan .
-
7 pharmaceutical companies including Rejing Bio announced their performance reports, and 5 companies reported good news
Time of Update: 2022-05-02
81% from the same period of the previous year; net profit attributable to shareholders of the parent company was -176 million yuan, compared with the previous year.
10% over the same period of the previous year; the net profit attributable to shareholders of the parent company was 119 million yuan, a year-on-year increase.
-
The 100 billion blue ocean of the domestic pharmaceutical equipment market appears?
Time of Update: 2022-05-02
Therefore, with the emergence of a blue ocean in the domestic pharmaceutical machine market, domestic pharmaceutical machine companies also need to strengthen technological innovation, increase investment in research and development, build high-level equipment, and create strong market competitiveness .
-
The peptide drug market has broad prospects, but it still faces 3 major challenges
Time of Update: 2022-05-02
Compared with small molecules, the development of peptide drugs is more complicated, and the company may not be able to meet the challenges by itself, and it needs to cooperate with other companies at different stages .
At present, domestic companies in the CDMO field of peptide drugs include Ambio Pharmaceuticals, Sino Bio, Nuotai Bio, Asymchem, etc.
-
The latest guidelines for drug registration acceptance review have revised these
Time of Update: 2022-05-02
4 new items are added to the Guidelines for Acceptance and Review of Chemical Drug Registration Except for the General Amendment Office, the Guidelines for the Acceptance and Review of Chemical Drug Registration (Draft for Comment) have been revised accordingly in accordance with the relevant laws and regulations promulgated in recent years such as the Measures for the Administration of Drug Registration.
-
New addition to the list of breakthrough therapy drugs for the treatment of lung cancer
Time of Update: 2022-05-02
On March 1, Innovent Bio and Baoyuan Pharmaceutical jointly announced that talatinib has been included in the list of breakthrough therapy drugs by the Center for Drug Evaluation of the State Food and Drug Administration, and the proposed indication is a ROS1 tyrosine kinase inhibitor that has not been previously (TKI) therapy and ROS1 fusion-positive non-small cell lung cancer patients previously treated with a ROS1 TKI .
-
In 2022, domestic pharmaceutical companies will accelerate the market for original research drugs
Time of Update: 2022-05-02
Prior to this, Chengdu Baiyu Pharmaceutical entered the administrative approval stage with its generic apixaban tablet, which was reported to be produced in Category 4, and is expected to become the company's second over-reviewed antithrombotic drug.
-
Overview of domestic drug candidates in preparation for KRAS targets
Time of Update: 2022-05-02
In July 2020, BeiGene submitted a clinical trial application for this drug in China, and it has been approved for clinical use; in mid-January 2021, the CDE official website showed that the KRAS G12C inhibitor AMG 510 ( Sotorasib) was included in the proposed breakthrough therapy category, and the proposed indication is patients with locally advanced or metastatic non-small cell lung cancer carrying KRAS p.
-
In 2021, several companies in the pharmaceutical industry are happy and some are sad, and these pharmaceutical companies have suffered huge losses
Time of Update: 2022-05-02
For example, according to the more than 240 A-share pharmaceutical companies that have disclosed their performance forecasts, 13 pharmaceutical companies have a net profit of more than 2 billion yuan, which is gratifying .
-
Novartis Sandoz launches a generic version of Revlimid, the original BMS drug, facing impact!
Time of Update: 2022-05-02
CompilenewbornSince Bristol-Myers Squibb bought Celgene and its superblockbuster Revlimid (lenalidomide) for $74 billion in 2019, the company has been facing generics for the multiple myeloma star drug Prepare for the day of the shock .
-
CDE publishes "Guidelines for Drug Registration Acceptance Review (Draft for Comment)"
Time of Update: 2022-05-02
On February 18, CDE issued the "Guidelines for the Acceptance and Review of Drug Registration (Trial) (Draft for Comment)", soliciting opinions on three aspects: traditional Chinese medicine, chemical drugs, and biological products.
-
After the multinational pharmaceutical company spins off its business, it will set up a new company to go public
Time of Update: 2022-05-02
In 2020, Merck announced the split plan, the tumor, in-hospital products, vaccines and animal health businesses will continue to be retained, while a new company will be established for women's health products, mature products and biosimilar products and listed independently, which is expected to be completed in the first half of 2021.
-
Briefly analyze the market status and prospects of eight categories of domestic pharmaceutical equipment
Time of Update: 2022-05-02
In recent years, with the upgrading of pharmaceutical consumption, the research level of new preparations has been continuously improved, and the market of new preparations in China has also continued to expand, bringing opportunities to the preparation machinery and equipment industry .
-
Guiding Opinions on the Application of Principles in Paragraph 2 of Article 117 of the Drug Administration Law issued
Time of Update: 2022-05-02
On February 24, the General Department of the State Food and Drug Administration issued an announcement stating that in order to further standardize the handling of administrative punishment cases fo
-
Chain pharmacy giants accelerate the deployment of "dual channels", what should small and medium-sized chains do?
Time of Update: 2022-05-02
Since 2019, an increasing number of provinces and prefectures have introduced a "dual-channel" model, leveraging the flexibility of retail pharmacies to expedite the delivery of high-priced medicines covered by medical insurance outside the hospital .
-
Transformation of a large number of pharmacies: choose between professionalism and convenience
Time of Update: 2022-05-02
In accordance with the requirements of the Guangdong Provincial Food and Drug Administration, it will innovate the drug retail business model, lead and meet the diverse needs of community residents for 24-hour daily urgent needs for drugs, and promote the transformation of traditional pharmacies into community health convenience stores .
-
When the introduction of new drugs by pharmaceutical companies has become the norm, two major drawbacks are gradually emerging
Time of Update: 2022-05-02
4 billion yuan to introduce Dalian Wanchun Brin's first-in-class new drug GEF-H1 activator punabulin, and then with 30 million US dollars, obtained Tianguangshi's third-generation CD20 monoclonal antibody MIL62 in China.
-
3 pharmaceutical companies, R&D expenses announced in 2021
Time of Update: 2022-05-02
Zejing Pharmaceuticals The 2021 performance report disclosed by Zejing Pharmaceuticals shows that the company has a net loss of 414 million yuan in 2021 .
Huiyu Pharmaceutical's 2021 performance report shows that the company will invest 247 million yuan in research and development in 2021, an increase of 178.
